<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437538</url>
  </required_header>
  <id_info>
    <org_study_id>2017/830/1</org_study_id>
    <nct_id>NCT03437538</nct_id>
  </id_info>
  <brief_title>Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter</brief_title>
  <official_title>Reduction Ratio and Clearance of Middle Molecules During a Single Hemodialysis Session With Medium Cut-Off (MCO) Filter Compared to Hemodiafiltration (HDF) With Standard High-flux Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Medium Cut-Off dialysis (MCO) membrane has been developed to improve middle molecule
      removal compared to standard high-flux dialysis filters.

      The major aim of this study is to compare the reduction ratio of middle molecules, during a
      single hemodialysis session with MCO-filter, compared to hemodiafiltration (HDF) with
      standard high-flux filter.

      Secondary aims are to compare the reduction ratio of small and large molecules between the
      treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Actual">April 16, 2019</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction ratio (RR) of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>120 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)</measure>
    <time_frame>240 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RR of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>4 hours</time_frame>
    <description>Reduction ratio during a 4h dialysis session. (Predialysis concentration - Postdialysis concentration)/Predialysis concentration*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of adverse events during a 4h dialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>120 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)</measure>
    <time_frame>240 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 30 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 60 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>120 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 120 minutes of dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)</measure>
    <time_frame>240 minutes</time_frame>
    <description>Instantaneous arteriovenous clearance (ml/min) at 240 minutes of dialysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <condition>Uremia</condition>
  <condition>Dialysis</condition>
  <arm_group>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MCO-HD</intervention_name>
    <description>Measurements will be done during a single hemodialysis session with Medium Cut-Off filter</description>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flux HDF</intervention_name>
    <description>Measurements will be done during a single hemodiafiltration session with standard high-flux filter</description>
    <arm_group_label>First High-flux-HDF, then MCO-HD</arm_group_label>
    <arm_group_label>First MCO-HD, then High-flux-HDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ongoing HDF treatment

          -  CRP &lt;30

          -  No Acute Myocardial Infarction within 3 months.

        Exclusion Criteria:

          -  Not able to understand the study information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Christensson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane, Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>MCO</keyword>
  <keyword>Middle molecules</keyword>
  <keyword>High Retention Onset</keyword>
  <keyword>Medium Cut-Off</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

